---
document_datetime: 2025-08-19 19:40:12
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/usymro-epar-all-authorised-presentations_en.pdf
document_name: usymro-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0934679
conversion_datetime: 2025-12-29 21:08:18.791704
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented)   | Strength   | Pharmaceutical                        | Route of Administration   | Immediate Packaging        | Content           | Pack size            |
|------------------|--------------|------------|---------------------------------------|---------------------------|----------------------------|-------------------|----------------------|
|                  | name         |            | Form                                  |                           |                            | (concentration)   |                      |
| EU/1/25/1957/001 | Usymro       | 45 mg      | Solution for injection                | Subcutaneous use          | vial (glass)               | 0.5 ml (90 mg/ml) | 1 vial               |
| EU/1/25/1957/002 | Usymro       | 45 mg      | Solution for injection                | Subcutaneous use          | pre-filled syringe (glass) | 0.5 ml (90 mg/ml) | 1 pre-filled syringe |
| EU/1/25/1957/003 | Usymro       | 90 mg      | Solution for injection                | Subcutaneous use          | pre-filled syringe (glass) | 1.0 ml (90 mg/ml) | 1 pre-filled syringe |
| EU/1/25/1957/004 | Usymro       | 130 mg     | Concentrate for solution for infusion | Intravenous use           | vial (glass)               | 26 ml (5 mg/ml)   | 1 vial               |